中東およびアフリカの全エクソームシーケンシング市場、コンポーネント別（第 2 世代シーケンシングと第 3 世代シーケンシング）、製品とサービス別（システム、キット、サービス）、アプリケーション別（医薬品の発見と開発、農業と動物の研究、診断、個別化医療など）、エンドユーザー別（製薬およびバイオテクノロジー企業、学術研究機関、病院と診療所、臨床検査室など）、流通チャネル別（直接取引、小売販売など）、業界動向と 2029 年までの予測。
市場分析と洞察
中東およびアフリカの全エクソームシーケンシング市場は、2022年から2029年の予測期間に市場の成長が見込まれています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に8.2％のCAGRで成長すると分析しています。医療費と資金の増加は、予測期間における市場の需要を推進する主な原動力です。
しかし、全エクソーム配列解析の治療に伴う副作用は、全エクソーム配列解析市場の将来の成長を妨げる可能性があります。主要な市場プレーヤーによるパートナーシップや買収などの戦略的提携の採用は、全エクソーム配列解析市場の成長の機会として機能します。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
コンポーネント別（第2世代シーケンシングと第3世代シーケンシング）、製品とサービス別（システム、キット、サービス）、アプリケーション別（医薬品の発見と開発、農業と動物の研究、診断、個別化医療、その他）、エンドユーザー別（製薬およびバイオテクノロジー企業、学術研究機関、病院と診療所、臨床検査室、その他）、流通チャネル別（直接取引、小売販売、その他） |
|
対象国 |
サウジアラビア、南アフリカ、UAE、イスラエル、エジプト、その他の中東およびアフリカ |
|
対象となる市場プレーヤー |
Thermo Fisher Scientific Inc.、QIAGEN、Illumina, Inc.、Beckman Coulter, Inc.、Eurofins Scientific、BIONEER CORPORATION、ExoDx（Bio-Techne の一部）、FOUNDATION MEDICINE, INC.（F. Hoffmann-La Roche Ltd の子会社）、GeneFirst Limited、CeGaT GmbH、Meridian、Merck KGaA、SOPHiA GENETICS、Azenta US Inc.、CD Genomics、Twist Bioscience、PerkinElmer Genomics（PerkinElmer Inc. の子会社）、GeneDx, LLC、Psomagen、Integrated DNA Technologies, Inc. など。 |
全エクソームシークエンシング市場の定義
全エクソームは、ゲノム内の遺伝子のタンパク質コード領域全体を配列するゲノム技術です。全エクソーム配列決定は、複数の病状の統一的な診断を求めている患者が利用できます。個人のゲノムのエクソン（またはタンパク質コード）領域と関連配列のヌクレオチド配列を主に決定するために使用される実験室プロセスで、完全な DNA 配列の約 1% を占め、WES とも呼ばれます。全エクソーム配列決定は、ゲノムのタンパク質コード領域の配列決定を伴う、広く使用されている全エクソーム配列決定方法です。ヒトのエクソームはゲノムの 2% 未満を占めますが、既知の疾患関連変異の約 85% を含むため、この方法は全ゲノム配列決定のコスト効率に優れた代替手段となります。
エクソームエンリッチメントを使用したエクソームシーケンシングは、集団遺伝学、遺伝病、がん研究など、幅広いアプリケーションにわたってコーディングバリアントを効率的に検出できます。世界的な全エクソームシーケンシング市場の成長は、シーケンシングの時間とコストの削減に起因しています。新しい技術とがん治療法の開発により、臨床腫瘍学における全エクソームシーケンシング市場は今後数年間で大きな可能性を秘めています。
中東およびアフリカの全エクソームシークエンシング市場の動向
ドライバー
- 次世代シーケンシング（NGS）の採用の増加
ゲノミクスに焦点を当てた薬理学がさまざまな慢性疾患、特に癌の治療において大きな役割を果たし続けるにつれて、次世代シーケンシング (NGS) は、個々の腫瘍や特定の受容体の分子基盤に対するより深く正確な洞察を提供する強力なツールとして進化しています。
NGS は従来の方法に比べて精度、感度、速度の面で優れており、腫瘍学の分野に大きな影響を与える可能性があります。NGS では 1 回のアッセイで複数の遺伝子を評価できるため、原因となる変異を特定するために複数のテストを注文する必要がなくなります。
- 標的シーケンシング法の利用増加
ゲノミクスに焦点を当てた薬理学がさまざまな慢性疾患、特に癌の治療において大きな役割を果たし続けるにつれて、次世代シーケンシング (NGS) は、個々の腫瘍や特定の受容体の分子基盤に対するより深く正確な洞察を提供する強力なツールとして進化しています。
NGS は従来の方法に比べて精度、感度、速度の面で優れており、腫瘍学の分野に大きな影響を与える可能性があります。NGS では 1 回のアッセイで複数の遺伝子を評価できるため、原因となる変異を特定するために複数のテストを注文する必要がなくなります。
拘束
-
エクソンの網羅性が低い
すべてのエクソンが包括的に捕捉されているわけではありません。重要なエクソンは、ヒトゲノムの現在の標準注釈には含まれていない可能性があり、現在の WES 技術でエクソンの 100% をカバーするのは困難です。その結果、これらの「見逃された」エクソン内の疾患を引き起こす変異は検出されません。
WESは構造変異に対する感度が低いため、検出範囲が限られています。それでも、インデルや重複を含む一部のCNVはWESで検出できますが、技術的な制限により、他のCNVは見逃される可能性があります。
機会
-
主要市場プレーヤーによる戦略的取り組み
The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.
Challenge
- Ethical and legal issues related to whole exome sequencing
Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patient and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing (WES) studies.
Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.
Post COVID-19 Impact on Whole Exome Sequencing Market
COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.
Recent Development
- In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
- In March, 2022, several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA seeks to educate healthcare providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes. This has helped company to adhere to guidelines.
Middle East & Africa Whole Exome Sequencing Market Segmentation
Middle East & Africa whole exome sequencing market is segmented on the basis of component, product and service, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Component
- Second-Generation Sequencing
- Third-Generation Sequencing
On the basis of component, the Middle East & Africa whole exome sequencing market is segmented into second-generation sequencing and third-generation sequencing.
Product and Services
- Systems
- Kits
- Services
On the basis of product and service, the Middle East & Africa whole exome sequencing market is segmented into systems, kits and services.
Application
- Diagnostics
- Drug Discovery and Development
- Personalized Medicine
- Agriculture & Animal Research
- Others
On the basis of application, the Middle East & Africa whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
End User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Laboratories
- Others
On the basis of end user, the Middle East & Africa whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, clinical laboratories and others.
Distribution Channel
- Direct Trade
- Retail sales
- Others
On the basis of distribution channel, the Middle East & Africa whole exome sequencing market is segmented into direct trade, retail sales and others.
Whole Exome Sequencing Market Country Level Analysis
The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user and distribution channel.
The countries covered in the whole exome sequencing market report are Saudi Arabia, South Africa, UAE, Israel, Egypt and Rest of Middle East & Africa.
South Africa is going to dominating in forecast period due to the Increase in acceptance of next generation sequencing methods for prediction, treatment. South Africa is expected to grow due to monitoring of diverse chronic diseases such as cancer.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Whole exome sequencing market also provides you with detailed market analysis for every country growth in healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding whole exome sequencing market.
Competitive Landscape and Whole Exome Sequencing Market Share Analysis
Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Whole exome sequencing market.
The major companies which are dealing in the s Whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 INDUSTRIAL INSIGHTS:
4.4 CONCLUSION
5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 GROWING USAGE OF TARGETED SEQUENCING METHODS
6.1.2 INCREASE IN THE ADOPTION OF NEXT GENERATION SEQUENCING
6.1.3 INCREASING DIAGNOSTICS APPLICATIONS OF WHOLE EXOME SEQUENCING
6.1.4 INCREASE TREND TOWARD PERSONALIZED MEDICATION
6.2 RESTRAINTS
6.2.1 LESS COMPREHENSIVE COVERAGE OF EXONS
6.2.2 CYBER SECURITY CONCERNS IN GENOMICS
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
6.3.2 INCREASING PRODUCT LAUNCHES IN RECENT YEARS
6.4 CHALLENGES
6.4.1 LACK OF SKILLED PROFESSIONALS
6.4.2 ETHICAL AND LEGAL ISSUES RELATED TO WHOLE EXOME SEQUENCING
7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT
7.1 OVERVIEW
7.2 SECOND-GENERATION SEQUENCING
7.2.1 SEQUENCING BY SYNTHESIS (SBS)
7.2.2 SEQUENCING BY HYBRIDIZATION (SBH) AND SEQUENCING BY LIGATION (SBL)
7.3 THIRD-GENERATION SEQUENCING
8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE
8.1 OVERVIEW
8.2 SYSTEMS
8.2.1 HISEQ SERIES
8.2.1.1 HISEQ 2500
8.2.1.2 HISEQ 1500
8.2.2 MISEQ SERIES
8.2.3 ION TORRENT PLATFORMS
8.2.3.1 ION PROTON
8.2.3.2 ION PGM
8.2.4 OTHERS
8.3 KITS
8.3.1 DNA FRAGMENTATION, END REPAIR, A-TAILING, AND SIZE SELECTION KITS
8.3.2 LIBRARY PREPARATION KITS
8.3.3 TARGET ENRICHMENT KITS
8.3.4 OTHERS
8.4 SERVICES
8.4.1 SEQUENCING SERVICES
8.4.2 DATA ANALYSIS (BIOINFORMATICS) SERVICES
8.4.3 OTHERS
9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 DRUG DISCOVERY AND DEVELOPMENT
9.3 AGRICULTURE & ANIMAL RESEARCH
9.4 DIAGNOSTICS
9.5 PERSONALIZED MEDICINE
9.6 OTHERS
10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER
10.1 OVERVIEW
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
10.3 ACADEMIC & RESEARCH INSTITUTES
10.4 HOSPITALS AND CLINICS
10.5 CLINICAL LABORATORIES
10.6 OTHERS
11 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 DIRECT TRADE
11.3 RETAIL SALES
11.4 OTHERS
12 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY REGION
12.1 MIDDLE EAST AND AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 U.A.E
12.1.4 ISRAEL
12.1.5 EGYPT
12.1.6 REST OF MIDDLE EAST AND AFRICA
13 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
14 COMPANY PROFILE
14.1 PERKINELMER GENOMICS (A SUBSIDIARY OF PERKINELMER INC.)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COM PANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 MERCK KGAA
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COM PANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 EXODX (A PART OF BIO-TECHNE)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COM PANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 THERMO FISHER SCIENTIFIC INC.
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COM PANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 FOUNDATION MEDICINE, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COM PANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 AZENTA US, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 PRODUCT PORTFOLIO
14.6.3 RECENT DEVELOPMENTS
14.7 BECKMAN COULTER, INC
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENTS
14.8 BIONEER CORPORATION
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENTS
14.9 CD GENOMICS
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 CEGAT GMBH
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENTS
14.11 EUROFINS SCIENTIFIC
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 GENEDX, LLC
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GENEFIRST LIMITED.
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.14 ILLUMINA, INC
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGRATED DNA TECHNOLOGIES, INC.
14.15.1 COMPANY SNAPSHOT
14.15.2 PRODUCT PORTFOLIO
14.15.3 RECENT DEVELOPMENTS
14.16 MERIDIAN BIOSCIENCE, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 REVENUE ANALYSIS
14.16.3 PRODUCT PORTFOLIO
14.16.4 RECENT DEVELOPMENTS
14.17 PSOMAGEN
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 QIAGEN
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 SOPHIA GENETICS
14.19.1 COMPANY SNAPSHOT
14.19.2 REVENUE ANALYSIS
14.19.3 PRODUCT PORTFOLIO
14.19.4 RECENT DEVELOPMENTS
14.2 TWIST BIOSCIENCE
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA THIRD-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA DRUG DISCOVERY AND DEVELOPMENT IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA AGRICULTURE & ANIMAL RESEARCH IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA DIAGNOSTICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA PERSONALIZED MEDICINE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA ACADEMIC & RESEARCH INSTITUTES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA HOSPITALS AND CLINICS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA CLINICAL LABORATORIES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA DIRECT TRADE IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA RETAIL SALES IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA OTHERS IN WHOLE EXOME SEQUENCING MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 42 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 43 SOUTH AFRICA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 44 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 45 SOUTH AFRICA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 46 SOUTH AFRICA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 47 SOUTH AFRICA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 48 SOUTH AFRICA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 49 SOUTH AFRICA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 54 SAUDI ARABIA SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 55 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 56 SAUDI ARABIA SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 57 SAUDI ARABIA HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 58 SAUDI ARABIA ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 64 U.A.E WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 65 U.A.E SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 66 U.A.E WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 67 U.A.E SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 68 U.A.E HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 69 U.A.E ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 70 U.A.E KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 71 U.A.E SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 72 U.A.E WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 U.A.E WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 74 U.A.E WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 75 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 76 ISRAEL SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 77 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 78 ISRAEL SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 79 ISRAEL HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 80 ISRAEL ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 81 ISRAEL KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 82 ISRAEL SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 83 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 85 ISRAEL WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 86 EGYPT WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 87 EGYPT SECOND-GENERATION SEQUENCING IN WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
TABLE 88 EGYPT WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 89 EGYPT SYSTEMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 90 EGYPT HISEQ SERIES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 91 EGYPT ION TORRENT PLATFORMS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 92 EGYPT KITS IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 93 EGYPT SERVICES IN WHOLE EXOME SEQUENCING MARKET, BY PRODUCT AND SERVICE, 2020-2029 (USD MILLION)
TABLE 94 EGYPT WHOLE EXOME SEQUENCING MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 95 EGYPT WHOLE EXOME SEQUENCING MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 EGYPT WHOLE EXOME SEQUENCING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 REST OF MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET, BY COMPONENT, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: REGIONAL VS COUNTRY MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET: SEGMENTATION
FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 INCREASE IN USE OF WES TECHNOLOGY FOR NEW SCIENTIFIC APPLICATIONS AND INCREASING THE PREFERENCE OF WES OVER WHOLE-GENOME SEQUENCING IS ITS LOW-COST SEQUENCING CAPABILITY IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 THE INSTRUMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING (WES) MARKET IN 2022 & 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF THE MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET
FIGURE 15 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2021
FIGURE 16 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, 2022-2029 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, CAGR (2022-2029)
FIGURE 18 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2021
FIGURE 20 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, 2022-2029 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, CAGR (2022-2029)
FIGURE 22 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY PRODUCT AND SERVICE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2021
FIGURE 24 LOBAL WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 26 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2021
FIGURE 28 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, CAGR (2022-2029)
FIGURE 30 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY END USER, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 32 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 34 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: SNAPSHOT (2021)
FIGURE 36 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021)
FIGURE 37 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 38 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 39 MIDDLE EAST AND AFRICA WHOLE EXOME SEQUENCING MARKET: BY COMPONENT (2022-2029)
FIGURE 40 MIDDLE EAST & AFRICA WHOLE EXOME SEQUENCING MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
